| First Author | Zumkehr J | Year | 2015 |
| Journal | Neurobiol Aging | Volume | 36 |
| Issue | 7 | Pages | 2260-2271 |
| PubMed ID | 25964214 | Mgi Jnum | J:224488 |
| Mgi Id | MGI:5662346 | Doi | 10.1016/j.neurobiolaging.2015.04.005 |
| Citation | Zumkehr J, et al. (2015) Ceftriaxone ameliorates tau pathology and cognitive decline via restoration of glial glutamate transporter in a mouse model of Alzheimer's disease. Neurobiol Aging 36(7):2260-2271 |
| abstractText | Glial glutamate transporter, GLT-1, is the major Na(+)-driven glutamate transporter to control glutamate levels in synapses and prevent glutamate-induced excitotoxicity implicated in neurodegenerative disorders including Alzheimer's disease (AD). Significant functional loss of GLT-1 has been reported to correlate well with synaptic degeneration and severity of cognitive impairment among AD patients, yet the underlying molecular mechanism and its pathological consequence in AD are not well understood. Here, we find the temporal decrease in GLT-1 levels in the hippocampus of the 3xTg-AD mouse model and that the pharmacological upregulation of GLT-1 significantly ameliorates the age-dependent pathological tau accumulation, restores synaptic proteins, and rescues cognitive decline with minimal effects on Abeta pathology. In primary neuron and astrocyte coculture, naturally secreted Abeta species significantly downregulate GLT-1 steady-state and expression levels. Taken together, our data strongly suggest that GLT-1 restoration is neuroprotective and Abeta-induced astrocyte dysfunction represented by a functional loss of GLT-1 may serve as one of the major pathological links between Abeta and tau pathology. |
